This is a copy of the “We PAID Act” by Senators Chris van Hollen (D-MD) and Rick Scott (R-FL). The We PAID Act The 31 page bill creates a new non-profit organization to determine reasonable prices for drugs that use… Continue Reading
KEI letter to FTC regarding interoperability remedies to address unlawful and anti-competitive actions by Facebook Today KEI sent a letter to the U.S. Federal Trade Commission (FTC), asking that the FTC require Facebook to extend interoperability remedies to third party… Continue Reading
Today the World Health Assembly (WHA) approved A72/A/CONF./2 Rev.1 as a resolution, titled “Improving the transparency of markets for medicines, vaccines, and other health products.” Link to the resolution: http://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_ACONF2Rev1-en.pdf When the text was made available, I sent out a… Continue Reading
One of the reasons why drug companies have fought so hard to block transparency of clinical trial costs is the growing gap between what the public had been told those costs are, and the actual costs, particularly for treatments for… Continue Reading
An earler version of this was posted to ip-health. —– As the #TransparencyResolution finally moves onto the #WHA72 agenda, I would like to offer a few comments on the process. We have copies of six versions of the negotiating text,… Continue Reading
The WHO has published A72/A/CONF./2, for Agenda item 11.7. The date of the document is 23 May 2019, but it is the end of day negotiating text from Wed, May 22. The title is: Improving the transparency of markets for… Continue Reading
Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- and gene-therapies and… Continue Reading
Politico has published a copy of the new draft of the World Health Assembly (WHA) transparency resolution. WHA-Resolution_DRAFT_20-05-2019 The Politico account cites the disclosure of clinical trial costs as one area for transparency that is strongly opposed by some governments,… Continue Reading
At the May 7 informal, countries from Northern Europe with strong pharma industry lobbies proposed dozens of changes in the transparency resolution to make it weaker and in many cases confusing and meaningless. This table compares the two texts: Dif-April29-May7-WHA-Transparency-Resolution… Continue Reading